Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 101,11 € (+150,21 %). Medianen er 106,83 € (+164,37 %).
| Køb |
16 |
| Behold |
6 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Arrowhead: positive Phase‑1/2a topline data for dual RNAi therapy ARO‑DIMER‑PA
Arrowhead reports preliminary topline results from the Phase‑1/2a study of ARO‑DIMER‑PA, an RNAi therapeutic designed to simultaneously silence PCSK9 and APOC3. After a single dose, mean maximal reductions of 72% for PCSK9 and 88% for APOC3 were observed; LDL cholesterol fell by 54% and triglycerides by 73%. Dose escalation proceeded up to 400 mg; the most common adverse events were injection‑site reactions and headache, and there were no drug‑related serious adverse events. The study is ongoing with multiple‑dose cohorts, and additional data are expected to be presented at an upcoming conference. » Mere på de.investing.com
Arrowhead prepares launch of Plozasiran and highlights strong SHASTA data
At the Cantor Fitzgerald conference, Arrowhead presented launch plans for Plozasiran and emphasized pooled SHASTA-3/4 data showing up to 81% triglyceride reduction and a 78% reduction in acute pancreatitis events, along with a favorable safety profile. The company plans to expand its field force from the current 5,000–6,000 to about 20,000 healthcare providers, favors home administration, and does not intend to out-license in the U.S. A list price of $45,000 (as with REDEMPLO for FCS) has reportedly not faced reimbursement pushback so far; a Priority Review Voucher is expected to bring the launch forward by four months. Arrowhead positioned Plozasiran as an easy-to-dose alternative to Olezarsen and sees large market potential in high-risk SHTG patients. » Mere på de.investing.com
Arrowhead will apply for FDA approval for Plozasiran in severe hypertriglyceridemia
Arrowhead presented positive phase-3 data on Plozasiran at the ESC Congress (studies SHASTA-3 and SHASTA-4): in 757 patients the drug reduced triglyceride levels versus placebo by 79% and 81% after 12 months. More than 90% of Plozasiran patients reached triglyceride levels under 500 mg/dL, and over half under 150 mg/dL. In a pooled analysis Plozasiran reduced acute pancreatitis events by 78% (by 91% in high‑risk patients). Arrowhead plans to submit a supplemental new drug application (sNDA) to the FDA by the end of 2026 and to use an acquired Priority Review Voucher; the safety profile showed treatment‑related events comparable to placebo. » Mere på de.investing.com
Arrowhead Pharmaceuticals becomes a commercial biopharma company with RNAi therapeutics
Arrowhead Pharmaceuticals develops highly precise RNAi therapeutics that selectively silence disease-causing genes and is leveraging a broad pipeline for commercialization. The company is shifting from a research operation to a revenue-generating provider with established partnerships with global pharmaceutical companies. With novel treatments in the cardiometabolic area, Arrowhead is targeting potentially multi-billion-dollar markets. » Mere på finanzen.net
Arrowhead beats revenue forecasts in Q3 thanks to rapid launch of REDEMPLO
Arrowhead reported revenue of $75.2 million in the third quarter of 2026, significantly exceeding expectations, while net loss widened to $1.36 per share. Revenue growth was driven by collaboration income and initial commercial sales of REDEMPLO; prescription volume and partnership revenues from Sarepta, Novartis and Madrigal rose markedly. Phase‑III studies in severe hypertriglyceridemia (SHTG) met all endpoints, and a supplemental approval filing is planned before the end of 2026, with management viewing SHTG as the next major growth driver. Arrowhead is expanding its sales force and pipeline but remains unprofitable as R&D and SG&A expenses increase; the stock reacted positively and approached its 52‑week high. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 33,37 mio. | 84,73 % |
| Bruttofortjeneste | 25,57 mio. | 88,30 % |
| Nettoresultat | -377,86 mio. | 1.767,08 % |
| EBITDA | -379,12 mio. | 792,98 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 6,14 mia. € |
Antal aktier | 141,25 mio. |
Højeste/laveste i 52 uger | 86,82 € - 33,70 € |
| Udbytte | Nej |
Beta | 1,37 |
P/E (PE Ratio) | -9,37 |
PEG (PEG Ratio) | -0,01 |
K/I (PB Ratio) | 134,18 |
P/S (PS Ratio) | 14,97 |
Virksomhedsprofil
Arrowhead Pharmaceuticals, Inc. udvikler medicin til behandling af svært behandelige sygdomme i USA. Virksomhedens produkter i pipelinen omfatter ARO-AAT, et RNA-interferens (RNAi) terapeutisk kandidatlægemiddel, der er i fase II-klinisk forsøg til behandling af leversygdomme forbundet med alfa-1-antitrypsinmangel; ARO-APOC3, som er i fase 2b og et fase 3-klinisk forsøg til behandling af hypertriglyceridæmi; ARO-ANG3, der er i fase 2b-klinisk forsøg til at reducere produktionen af angiopoietinlignende protein 3; ARO-HSD, som er i fase 1/2a-klinisk forsøg til behandling af leversygdomme; ARO-ENaC, som er i et fase 1/2a-klinisk forsøg til at reducere produktionen af den epiteliale natriumkanal alfa-underenhed i lungernes luftveje; ARO-C3 til behandling af komplementmedieret sygdom, som er i fase 1/2a-klinisk forsøg; ARO-Lung2 til behandling af kronisk obstruktiv lungesygdom; ARO-DUX4 til behandling af facioscapulohumeral muskeldystrofi; ARO-XDH til behandling af ukontrolleret gigt; ARO-COV til behandling af COVID-19 og andre luftbårne patogener i lungerne; og ARO-HIF2, som er i fase 1b-klinisk forsøg til behandling af clear cell nyrecellekarcinom. Virksomheden er desuden involveret i udviklingen af JNJ-3989, et subkutant administreret RNAi terapeutisk kandidatlægemiddel til behandling af kronisk hepatitis B-virusinfektion; Olpasiran til at reducere produktionen af apolipoprotein A; og ARO-AMG1 til behandling af genetisk validerede kardiovaskulære targets. Arrowhead Pharmaceuticals, Inc. har en licens- og forskningssamarbejdsaftale med Janssen Pharmaceuticals, Inc. om udvikling af ARO-JNJ1, ARO-JNJ2 og ARO-JNJ3 RNAi-terapeutika til leverudtrykte targets; og en licens- og forskningssamarbejdsaftale med Takeda Pharmaceuticals U.S.A., Inc. om udvikling af et RNAi terapeutisk kandidatlægemiddel til behandling af leversygdom. Arrowhead Pharmaceuticals, Inc. blev stiftet i 1989 og har hovedkontor i Pasadena, Californien.
| Navn | Arrowhead Pharmaceuticals |
| CEO | Christopher R. Anzalone |
| Hjemsted | Pasadena,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 16.12.1993 |
| Medarbejdere | 711 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ARWR |
London Stock Exchange | 0HI3.L |
Frankfurt | HDP1.F |
Düsseldorf | HDP1.DU |
London | 0HI3.L |
SIX | HDP1.SW |
München | HDP1.MU |